A year after MDMA-assisted therapy, a qualitative study documented the benefits veterans and first responders perceived — beyond their PTSD symptom scores.
A 2019 follow-up interviewed veterans and first responders a year after they took part in an MDMA-assisted therapy trial for PTSD.
This qualitative follow-up interviewed 19 of the 24 veterans, firefighters, and police officers who had completed an MDMA-assisted therapy trial for chronic, treatment-resistant PTSD, a year after treatment. Rather than measuring symptoms, it analyzed their own accounts to document benefits they perceived beyond symptom reduction. It's a qualitative complement to the trial's numbers — rich in lived detail, but not a measurement of whether symptoms improved, and drawn from a single small cohort.
This qualitative study used interpretative phenomenological analysis of semi-structured interviews with 19 of 24 participants (veterans, firefighters, police officers with chronic treatment-resistant PTSD) at their one-year follow-up after a Phase 2 MDMA-assisted psychotherapy trial, to complement the trial's CAPS-IV symptom data by documenting perceived benefits beyond symptom reduction.
As a qualitative analysis, this does not measure symptom change or establish efficacy; its value is descriptive, surfacing dimensions of benefit that quantitative scales miss. It draws on a single trial cohort of 19 and reflects participants' self-described experiences. Read it as a complement to — not evidence of — the trial's outcomes.
This analysis accompanies the Phase 2 MDMA-assisted therapy trial in veterans and first responders that reported large, sustained PTSD reductions (Mithoefer et al., 2018). Qualitative accounts like these shape how the field frames the therapy's mechanisms beyond symptom scores, but cannot substitute for controlled outcome data.
Read the full paper →